Interview with Professor Philippe Rouanet about the upcoming 'RESET' study which will take place during the New Trials Forum at ESCP’s 14th Annual Meeting in Vienna.
Professor Philippe Rouanet, internationally renowned expert in minimally invasive and robotic surgery and experienced proctor in robotic surgery at the Institut du Cancer de Montpellier (ICM), will present the RESET study, as chief investigator, during the New Trials Forum session in Vienna.
Rectal cancer is relatively common, with almost 40,000 new cases estimated for 2017 in the USA alone. The standard of care for its treatment is total mesorectal excision (TME) using several surgical techniques. However those techniques are in constant evolution and the research in the field of colorectal surgery is currently expanding.
Professor Rouanet presents the following question:
"What then could be the next step? Would there be a trial able to discriminate between the four major surgical techniques (open approach, laparoscopy, robotic approach and TaTME) for rectal cancer surgery? This question is essential, both for our junior surgeons and our senior colleagues who are willing to improve their technique."
The European multicentre study, Rectal Surgical Evaluation Trial (RESET) - coordinated by Professor Rouanet, endorsed by the European Society of Coloproctology (ESCP) and in partnership with Intuitive - aims to answer those questions. Professor Rouanet explains:
"Comparison of the open, laparoscopic and robotic approaches is needed, particularly compared with the transanal approach. The main objective of this study is to collect data from those four surgical techniques in order to help determine which technique may provide optimal outcomes for the most high-risk patients, i.e. those who are most difficult to operate, such as obese patients with narrow pelvis, large mesorectum, large tumour or bulky prostate."
The prospective, four parallel, casematched cohorts and observational Rectal Surgery Evaluation Trial (RESET), will select centres with expertise in these procedures. The study will be performed in a quality-controlled manner to avoid learning curve concerns while ensuring adequate enrolment for clinical relevance.
45 centers and 12 countries will be involved in the project during four years.
Trials sessions
New Trials Forum: MIRCAST Study and RESET Trial
Date: Thursday 26 September 2019
Time: 07:45-09:15
Investigators Meeting: MIRCAST Study and RESET Trial
Date: Thursday 26 September 2019
Time: 10:10-11:25
